The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic value of serum carbohydrate 19-9 in patients receiving gemcitabine-based neoadjuvant therapy for pancreatic cancer.
Kabir Mody
No relevant relationships to disclose
Joseph J. Shatzel
No relevant relationships to disclose
Spencer L. James
No relevant relationships to disclose
Rebecca Wang
No relevant relationships to disclose
Thomas Anthony Colacchio
No relevant relationships to disclose
Richard J. Barth
No relevant relationships to disclose
Bassem I. Zaki
No relevant relationships to disclose
Michael J. Tsapakos
No relevant relationships to disclose
Arief A. Suriawinata
No relevant relationships to disclose
John E. Sutton
No relevant relationships to disclose
Stuart R. Gordon
No relevant relationships to disclose
Timothy B. Gardner
No relevant relationships to disclose
Kerrington D. Smith
No relevant relationships to disclose
Gregory H. Ripple
No relevant relationships to disclose
Kathryn Cunningham Hourdequin
No relevant relationships to disclose
Gregory J. Tsongalis
No relevant relationships to disclose
Elizabeth Boutin McGrath
No relevant relationships to disclose
J. Marc Pipas
No relevant relationships to disclose